Patients who have had a stroke in the back of the brain are at greater risk of having another within two years if blood flow to the region is diminished, according to results of a multicenter study led by researchers at the University of Illinois at Chicago (UIC).


Statins are lifesaving medications — they have been shown to greatly reduce heart attack and other related events by more than 30 percent — yet patient compliance is a significant problem.[1] Studies estimate that up to 50 percent of patients with cardiovascular disease stop taking their statin medications as directed.[2]  Many do so because they experience statin induced myopathy, the onset of muscle aches, spasms and pain associated with statin therapy.

Trinity Biotech plc announced submission of its Meritas Point of Care Analyzer and Meritas cardiac troponin-I (cTnI) point-of-care assay for U.S. Food and Drug Administration (FDA) 510(k) clearance.

December 22, 2015 - The U.S. Food and Drug Administration has cleared the Zoll LifeVest Wearable Cardioverter Defibrillator, Models 3000, 3100, and 4000, for the additional indication treating pediatric patients 

December 22, 2015 — The American College of Cardiology (ACC) has launched a new Society of Thoracic Surgeons (STS)/ACC Transcatheter Aortic Valve Replacement (TAVR) In-Hospital Mortality Risk App and an extensively overhauled the ACC AnticoagEvaluator App, bolstering its expansive Clinical App Collection. With these new and improved apps, the ACC continues to diversify the clinical content and decision support it offers clinicians in the mobile space.

At the 101st Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), Siemens displayed new offerings for teamplay, a cloud-based network that helps link hospitals and healthcare experts, enabling them to exchange data and pool their knowledge.

December 22, 2015 — In 2015, results from the ITALIC and CvLPRIT trials, along with studies examining lifestyle factors contributing to heart failure, obstructive sleep apnea on atrial fibrillation recurrence and full body MRI in patients with an implantable cardioverter defibrillator (ICD) were among the top accessed research studies in the five journals published by the American College of Cardiology.

December 22, 2015 — Biotronik received U.S. Food and Drug Administration (FDA) approval for use of its latest family of implantable cardioverter defibrillator (ICD) systems with magnetic resonance imaging (MRI) scans. Biotronik ProMRI technology allows patients with approved device systems to have 1.5 Tesla MRI scans without an exclusion zone. ICD patients will have expanded access to MRI diagnostic scans, which can be critical for diagnosing conditions such as stroke, brain and cardiac tumors or orthopedic injuries.
 

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now